Ligand Reports Fourth Quarter and Full Year 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Ligand Pharma (LGND) Tops Q4 EPS by 43c, Offers Guidance
February 17, 2022 4:03 PM ESTLigand Pharma (NASDAQ: LGND) reported Q4 EPS of $1.80, $0.43 better than the analyst estimate of $1.37. Revenue for the quarter came in at $72.5 million versus the consensus estimate of $65.32 million.
GUIDANCE:
Ligand Pharma sees FY2022 revenue of $147-172 million, versus the consensus of... More
